SEC Form 4 · accession 0001562180-18-003539
WEST PHARMACEUTICAL SERVICES INC · WST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen Flynn
Officer — Sr VP & Chief Commercial Offic
Period of report
Aug 7, 2018
Accepted (ET)
Aug 9, 2018 · 10:59 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000105770
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 7, 2018 | M | 9,458 | $21.22 | A | 31,051 | D | |
| Common Stock | Aug 7, 2018 | M | 11,000 | $25.145 | A | 42,051 | D | |
| Common StockF1 | Aug 7, 2018 | S | 20,458 | $116.23 | D | 21,593 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F2 | $25.145 | Aug 7, 2018 | M | 11,000 | D | — | Jul 24, 2022 | Common Stock | 11,000 | 20,982 | D |
| Stock Options (Right to Buy)F3 | $21.22 | Aug 7, 2018 | M | 9,458 | D | — | Feb 21, 2022 | Common Stock | 9,458 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $116.00 to $116.635 inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
- F2This award vests in 4 equal annual installments beginning on 2/21/2013.
- F3This award vests in 4 equal annual installments beginning on 7/24/2013.